Duopharma Biotech gets premium valuation on vaccine development


Its rating is now a buy with a new discounted cashflow-derived target price of RM4 from RM3.30, which is at a 2% yield.

PETALING JAYA: Duopharma Biotech Bhd has been upgraded to a buy from a sell by RHB Research, given the increased clarity on its chances to participate in vaccine rolloutss in the country.

The research house also noted that its human insulin contract had also been extended.

Save 30% for ads-free and full access now!

Monthly Plan

RM13.90/month
RM9.73 only

Billed as RM9.73 for the 1st month then RM13.90 thereafters.

Annual Plan

RM12.33/month
RM8.63/month

Billed as RM103.60 for the 1st year then RM148 thereafters.

1 month

Free Trial

For new subscribers only


Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.

Follow us on our official WhatsApp channel for breaking news alerts and key updates!

Others Also Read


All Headlines:

Want to listen to full audio?

Unlock unlimited access to enjoy personalise features on the TheStar.com.my

Already a member? Log In